Investor Relations

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

* denotes a required field

Sign me up for

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest News

View All Press Releases
Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

Latest Presentation

Investor Presentation
View All Presentations

Latest Financial Results

Q3 2025

Quarter Ended September 30, 2025

Earnings Release

HTML PDF

10-Q

HTML PDF XBRL Zip

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

View 10-K

Company Information

Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens.

ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum is now approved by the U.S. Food and Drug Administration. Complete prescribing information and important safety information is available at www.zelsuvmi.com. Additionally, Pelthos acquired Xepi® (ozenoxacin) Cream, 1% a topical treatment for impetigo and Xeglyze® (abametapir) topical treatment for head lice in the 4th Quarter of 2025 with targeted commercial availability in the second half of 2026 and the first half of 2027 respectively.

View Executive Team View Board of Directors

IR Contacts

Company

Pelthos Therapeutics Inc.
4020 Stirrup Creek Drive
Suite 110
Durham, NC 27703
United States
T: 1.919.908.2400
contact@pelthos.com

Investor Relations

LifeSci Advisors, LLC
Mike Moyer, Managing Director
mmoyer@lifesciadvisors.com

Connect With Us